Back to today’s briefing

Story perspectives

Innovent Biologics' DOVBLERON® Approved for Lung Cancer Treatment

1/3/2025

50 11

Summary

Story summary

Innovent Biologics celebrates a significant milestone with the NMPA's approval of DOVBLERON® for adults battling ROS1-positive non-small cell lung cancer, fueled by promising outcomes from the TRUST-I trial. In a related finding, adults who were screened for inactivity during wellness visits boasted lower obesity, diabetes, and hypertension rates, highlighting the power of proactive health measures.

1 of 1

Story summary

Innovent Biologics celebrates a significant milestone with the NMPA's approval of DOVBLERON® for adults battling ROS1-positive non-small cell lung cancer, fueled by promising outcomes from the TRUST-I trial. In a related finding, adults who were screened for inactivity during wellness visits boasted lower obesity, diabetes, and hypertension rates, highlighting the power of proactive health measures.